

**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 61 to 76 of 2019**

Statements of Principles Nos. 61 to 76 of 2019 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 21 June 2019.

The Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). The day of commencement as specified in each of the Instruments is 22 July 2019. In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from [http://www.legislation.gov.au](http://www.comlaw.gov.au).

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is available on the Authority's website at <http://www.rma.gov.au>.

For further information contact:

The Registrar

Repatriation Medical Authority

GPO Box 1014

Brisbane Qld 4001

T +61 7 3815 9404

F +61 7 3815 9412

E info@rma.gov.au

27 June 2019

**SUMMARY OF CHANGES**

|  |  |  |  |
| --- | --- | --- | --- |
| **Instr. No.** | **Title** | **Date of Commencement** | **ICD-10-AM Code** |
| **REVOCATIONS** |
|  |  |  |  |
| 61 & 62/2019 | schistosomiasis | 22/07/2019 | B65 |
|  |  |  |  |
| 63 & 64/2019 | strongyloidiasis | 22/07/2019 | B78 |
|  |  |  |  |
| 65 & 66/2019 | irritable bowel syndrome | 22/07/2019 | K58 |
|  |  |  |  |
| 67 & 68/2019 | subarachnoid haemorrhage | 22/07/2019 | I60, S06.6 |
|  |  |  |  |
| 69 & 70/2019 | renal stone disease | 22/07/2019 | N20 |
|  |  |  |  |
| **AMENDMENTS** |
|  |  |  |  |
| 71 & 72/2019 | aortic aneurysm | 22/07/2019 | Nil |
|  |  |  |  |
| 73 & 74/2019 | osteoarthritis | 22/07/2019 | Nil |
|  |  |  |  |
| 75 & 76/2019 | morbid obesity | 22/07/2019 | Nil |
|  |  |  |  |

| **SUMMARY OF CHANGES** |
| --- |
| 61 & 62/2019 | schistosomiasis | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 8 May 2018 concerning *schistosomiasis* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH & BoP SoPs*** ***(Instrument Nos. 61 & 62/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'schistosomiasis' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'cutaneous or mucosal contact with water containing larvae';
* new factor in subsection 9(2) concerning 'having a solid organ transplant, where the organ is infected'; and
* new definitions of 'MRCA', 'VEA' in Schedule 1 - Dictionary; and
* revising the definition 'relevant service' in Schedule 1 – Dictionary.

**The determining of these Instruments finalises the investigation in relation to *schistosomiasis* as advertised in the Government Notices Gazette of 8 May 2018.** |
| 63 & 64/2019 | strongyloidiasis | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 8 May 2018 concerning *strongyloidiasis* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 63/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'strongyloidiasis' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(2) concerning 'having cutaneous or mucosal contact with *Strongyloides stercoralis* roundworm larvae';
* revising the factor in subsection 9(3) concerning 'having a solid organ transplant, where the organ is infected';
* revising the factor in subsection 9(4) concerning 'being in an immunocompromised state as specified';
* new factor in subsection 9(5) concerning 'having alcohol use disorder';
* new definitions of 'chronic renal failure', 'immunosuppressive drug', 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definitions of 'immunocompromised state as specified' and 'relevant service' in Schedule 1 – Dictionary.

***For BoP SoP (Instrument No. 64/2019**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'strongyloidiasis' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'having cutaneous or mucosal contact with *Strongyloides stercoralis* roundworm larvae';
* revising the factor in subsection 9(2) concerning 'having a solid organ transplant, where the organ is infected';
* revising the factor in subsection 9(3) concerning 'being in an immunocompromised state as specified';
* new factor in subsection 9(4) concerning 'having alcohol use disorder';
* new definitions of 'chronic renal failure', 'immunosuppressive drug', 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definitions of 'immunocompromised state as specified' and 'relevant service' in Schedule 1 – Dictionary.

**The determining of these Instruments finalises the investigation in relation to *strongyloidiasis* as advertised in the Government Notices Gazette of 8 May 2018.** |
| 65 & 66/2019 | irritable bowel syndrome | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 6 November 2018 concerning *irritable bowel syndrome* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 65/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of ' irritable bowel syndrome' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(2) & 9(9) concerning 'having a clinically significant disorder of mental health';
* new factors in subsections 9(4) & 9(11) concerning 'living or working in a hostile or life-threatening environment';
* new factors in subsections 9(5) & 9(12) concerning 'experiencing a category 1A stressor';
* new factors in subsections 9(6) & 9(13) concerning 'experiencing a category 1B stressor';
* new factors in subsections 9(7) & 9(14) concerning 'experiencing a category 2 stressor';
* new factor in subsection 9(8) concerning 'experiencing severe childhood abuse';
* new definitions of 'category 1A stressor', 'category 1B stressor', 'category 2 stressor', 'clinically significant disorder of mental health as specified', 'corpse', 'eyewitness', 'hostile or life-threatening environment', 'MRCA' ‘severe childhood abuse’ and 'VEA' in the Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definition of 'a specified psychiatric condition'.

***For BoP SoP*** ***(Instrument No. 66/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of irritable bowel syndrome in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(4) concerning 'having a clinically significant disorder of mental health';
* new factor in subsection 9(3) concerning 'experiencing severe childhood abuse';
* new definitions of 'clinically significant disorder of mental health as specified', 'MRCA' 'severe childhood abuse',and 'VEA' in the Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definition of 'a specified psychiatric condition'.

**The determining of these Instruments finalises the investigation in relation to *irritable bowel syndrome* as advertised in the Government Notices Gazette of 6 November 2018.** |
| 67 & 68/2019 | subarachnoid haemorrhage | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *subarachnoid haemorrhage* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 67/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'subarachnoid haemorrhage' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'physical activity', by the inclusion of a note;
* new factor in subsection 9(2) concerning 'concussion or moderate to severe traumatic brain injury';
* new factor in subsection 9(5) concerning 'undergoing childbirth or being within six weeks postpartum';
* revising the factor in subsection 9(6) concerning 'smoking', by the inclusion of a note;
* new factor in subsection 9(7) concerning 'antithrombotic therapy';
* revising the factor in subsection 9(8) concerning 'taking at least 700 milligrams of aspirin';
* revising the factor in subsection 9(9) concerning 'infective intracranial vasculitis';
* revising the factor in subsection 9(10) concerning 'inflammatory vascular disease';
* revising the factor in subsection 9(11) concerning 'alcohol', for males, by the inclusion of a note;
* revising the factor in subsection 9(12) concerning 'alcohol', for females, by the inclusion of a note;
* revising the factor in subsection 9(13) concerning 'a drug from the specified list of drugs';
* new factor in subsection 9(15) concerning 'an acquired disorder resulting in impaired haemostasis';
* new factor in subsection 9(16) concerning 'a course of therapeutic radiation for cancer';
* new factor in subsection 9(17) concerning 'being menopausal';
* new factor in subsection 9(18) concerning 'chronic renal failure';
* deleting the factor concerning 'cerebral trauma', as it is subsumed by the factor in subsection 9(2) concerning 'concussion or moderate to severe traumatic brain injury';
* deleting the factors concerning 'anticoagulant therapy' and 'thrombolytic therapy', as they are subsumed by the factor in subsection 9(7) concerning 'antithrombotic therapy';
* deleting the factor concerning 'an acquired haematological disorder', as it is subsumed by the factor in subsection 9(15) concerning 'an acquired disorder resulting in impaired haemostasis';
* deleting the factor concerning 'intracranial dissecting aneurysm';
* deleting the factor concerning 'statin medication';
* new definitions of 'antithrombotic therapy', 'chronic renal failure', 'MRCA', 'specified list of drugs', 'specified list of inflammatory vascular diseases' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'pack-year of cigarettes, or the equivalent thereof in other tobacco products' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a drug from the specified list', 'alcohol', 'an acquired haematological disorder from the specified list', 'an inflammatory vascular disease', 'anticoagulant therapy', 'cerebral trauma', 'intracranial dissecting aneurysm', 'intracranial infective vasculitis due to a specified infection' and 'thrombolytic therapy'.

***For BoP SoP*** ***(Instrument No. 68/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'subarachnoid haemorrhage' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'physical activity', by the inclusion of a note;
* new factor in subsection 9(2) concerning 'concussion or moderate to severe traumatic brain injury';
* revising the factor in subsection 9(5) concerning 'smoking' by the inclusion of a note;
* new factor in subsection 9(6) concerning 'antithrombotic therapy';
* revising the factor in subsection 9(7) concerning 'taking at least 700 milligrams of aspirin';
* revising the factor in subsection 9(8) concerning 'infective intracranial vasculitis';
* revising the factor in subsection 9(9) concerning 'inflammatory vascular disease';
* revising the factor in subsection 9(10) concerning 'alcohol', for males, by the inclusion of a note;
* revising the factor in subsection 9(11) concerning 'alcohol', for females, by the inclusion of a note;
* revising the factor in subsection 9(12) concerning 'a drug from the specified list of drugs';
* new factor in subsection 9(14) concerning 'an acquired disorder resulting in impaired haemostasis';
* deleting the factor concerning 'cerebral trauma', as it is subsumed by the factor in subsection 9(2) concerning 'concussion or moderate to severe traumatic brain injury';
* deleting the factors concerning 'anticoagulant therapy' and 'thrombolytic therapy', as they are subsumed by the factor in subsection 9(6) concerning 'antithrombotic therapy';
* deleting the factor concerning 'intracranial dissecting aneurysm';
* deleting the factor concerning 'statin medication';
* new definitions of 'antithrombotic therapy', 'chronic renal failure', 'MRCA', 'specified list of drugs', 'specified list of inflammatory vascular diseases' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'pack-year of cigarettes, or the equivalent thereof in other tobacco products' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a drug from the specified list', 'alcohol', 'an inflammatory vascular disease', 'anticoagulant therapy', 'intracranial dissecting aneurysm', 'intracranial infective vasculitis due to a specified infection', 'moderate to severe cerebral trauma' and 'thrombolytic therapy'.

**The determining of these Instruments finalises the investigation in relation subarachnoid haemorrhage as advertised in the Government Notices Gazette of 14 November 2017.**  |
| 69 & 70/2019 | renal stone disease | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *renal stone disease* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 69/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'renal stone disease' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(2) concerning 'primary hyperparathyroidism';
* new factor in subsection 9(3) concerning 'post-surgical hypoparathyroidism';
* revising the factor in subsection 9(5) concerning 'having a haematological disease';
* revising the factor in subsection 9(6) concerning 'gout or hyperuricaemia';
* new factor in subsection 9(7) concerning 'tumour lysis syndrome';
* revising the factor in subsection 9(8) concerning 'diarrhoea';
* new factor in subsection 9(10) concerning 'distal renal tubular acidosis';
* revising the factor in subsection 9(11) concerning 'a urinary tract infection';
* revising the factor in subsection 9(12) concerning 'an acquired narrowing or obstruction of the ureter, ureteropelvic junction or renal calyx';
* new factor in subsection 9(13) concerning 'having a gastrointestinal disease';
* new factor in subsection 9(14) concerning 'having undergone: (a) malabsorptive bariatric procedure; or (b) ileal resection or ileal bypass surgery; or (c) Roux-en-Y gastric bypass surgery';
* new factor in subsection 9(15) concerning 'having a systemic disease';
* revising the factor in subsection 9(16) concerning 'a drug or a drug from a class of drugs';
* new factor in subsection 9(17) concerning 'a vitamin D supplement';
* revising the factor in subsection 9(18) concerning 'a urinary diversion procedure'
* revising the factor in subsection 9(19) concerning 'neurogenic bladder';
* revising the factor in subsection 9(21) concerning 'being immobile';
* revising the factor in subsection 9(22) concerning 'inability to consume an average of at least 400 grams of calcium per day';
* new factor in subsection 9(23) concerning 'inadequate fluid intake';
* revising the factor in subsection 9(24) concerning 'being overweight or obese';
* revising the factor in subsection 9(26) concerning 'a renal transplant';
* revising the factor in subsection 9(27) concerning 'inhaling cadmium fumes';
* revising the factor in subsection 9(28) concerning 'experiencing spaceflight';
* deleting the factors concerning 'myeloproliferative disorder' and 'haemolytic anaemia' as they are subsumed by the factor in subsection 9(5) concerning 'having a haematological disease';
* deleting the factor concerning 'chemotherapy-induced tumour lysis' as it is subsumed by the factor in subsection 9(7) concerning 'tumour lysis syndrome';
* deleting the factors concerning 'inflammatory bowel disease', 'chronic pancreatitis' and 'biliary cirrhosis' as they are subsumed by the factor in subsection 9(13) concerning 'having a gastrointestinal disease';
* deleting the factors concerning 'Roux-en-Y gastric bypass surgery' and 'partial or complete ileal resection or ileal bypass surgery' as they are subsumed by the factor in subsection 9(14) concerning 'having undergone: (a) malabsorptive bariatric procedure; or (b) ileal resection or ileal bypass surgery; or (c) Roux-en-Y gastric bypass surgery';
* deleting the factors concerning 'type 2 diabetes mellitus', 'sarcoidosis' and 'Sjogren's syndrome' as they are subsumed by the factor in subsection 9(15) concerning 'having a systemic disease';
* deleting the factor concerning 'being bed-bound' as it is subsumed by the factor in subsection 9(21) concerning 'being immobile';
* deleting the factor concerning 'hyperthyroidism';
* deleting the factor concerning 'ingesting ethylene glycol or diethylene glycol';
* new definitions of 'being immobile', 'being overweight or obese', 'BMI', 'distal renal tubular acidosis', 'hyperuricaemia', 'malabsorptive bariatric procedure', 'MRCA', 'neurogenic bladder', 'specified list of drugs', 'specified list of gastrointestinal diseases', 'specified list of haematological diseases', 'specified list of systemic diseases', 'tumour lysis syndrome' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'inadequate fluid intake', 'relevant service', 'urease-producing bacteria' and 'urinary diversion procedure' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a drug or a drug from a class of drugs from the specified list', 'bed-bound' and 'being obese'.

***For BoP SoP*** ***(Instrument No. 70/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'renal stone disease' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'primary hyperparathyroidism';
* new factor in subsection 9(2) concerning 'post-surgical hypoparathyroidism';
* revising the factor in subsection 9(4) concerning 'having a haematological disease';
* revising the factor in subsection 9(5) concerning 'gout or hyperuricaemia';
* new factor in subsection 9(6) concerning 'tumour lysis syndrome';
* revising the factor in subsection 9(7) concerning 'diarrhoea';
* new factor in subsection 9(9) concerning 'distal renal tubular acidosis';
* revising the factor in subsection 9(10) concerning 'a urinary tract infection';
* revising the factor in subsection 9(11) concerning 'an acquired narrowing or obstruction of the ureter, ureteropelvic junction or renal calyx';
* new factor in subsection 9(12) concerning 'having a gastrointestinal disease';
* new factor in subsection 9(13) concerning 'having undergone: (a) malabsorptive bariatric procedure; or (b) ileal resection or ileal bypass surgery; or (c) Roux-en-Y gastric bypass surgery';
* new factor in subsection 9(14) concerning 'having a systemic disease';
* revising the factor in subsection 9(15) concerning 'a drug or a drug from a class of drugs';
* revising the factor in subsection 9(16) concerning 'a urinary diversion procedure'
* revising the factor in subsection 9(17) concerning 'neurogenic bladder';
* revising the factor in subsection 9(19) concerning 'being immobile';
* new factor in subsection 9(20) concerning 'inadequate fluid intake';
* revising the factor in subsection 9(21) concerning 'being overweight or obese';
* revising the factor in subsection 9(23) concerning 'a renal transplant';
* revising the factor in subsection 9(24) concerning 'experiencing spaceflight';
* deleting the factors concerning 'myeloproliferative disorder' and 'haemolytic anaemia' as they are subsumed by the factor in subsection 9(4) concerning 'having a haematological disease';
* deleting the factor concerning 'chemotherapy-induced tumour lysis' as it is subsumed by the factor in subsection 9(6) concerning 'tumour lysis syndrome';
* deleting the factors concerning 'inflammatory bowel disease', 'chronic pancreatitis' and 'biliary cirrhosis' as they are subsumed by the factor in subsection 9(12) concerning 'having a gastrointestinal disease';
* deleting the factors concerning 'Roux-en-Y gastric bypass surgery' and 'partial or complete ileal resection or ileal bypass surgery' as they are subsumed by the factor in subsection 9(13) concerning 'having undergone: (a) malabsorptive bariatric procedure; or (b) ileal resection or ileal bypass surgery; or (c) Roux-en-Y gastric bypass surgery';
* deleting the factors concerning 'type 2 diabetes mellitus', 'sarcoidosis' and 'Sjogren's syndrome' as they are subsumed by the factor in subsection 9(14) concerning 'having a systemic disease';
* deleting the factor concerning 'being bed-bound' as it is subsumed by the factor in subsection 9(19) concerning 'being immobile';
* deleting the factor concerning 'hyperthyroidism';
* new definitions of 'being immobile', 'being overweight or obese', 'BMI', 'distal renal tubular acidosis', 'hyperuricaemia', 'malabsorptive bariatric procedure', 'MRCA', 'neurogenic bladder', 'specified list of drugs', 'specified list of gastrointestinal diseases', 'specified list of haematological diseases', 'specified list of systemic diseases', 'tumour lysis syndrome' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'inadequate fluid intake', 'relevant service', 'urease-producing bacteria' and 'urinary diversion procedure' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a drug or a drug from a class of drugs from the specified list', 'bed-bound' and 'being obese'.

**The determining of these Instruments finalises the investigation in relation to *renal stone disease* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 71 & 72/2019 | aortic aneurysm | **Amendment**These instruments amend Statements of Principles Nos. 9 & 10 of 2012 concerning ***aortic aneursym*** by:***For RH SoP*** ***(Instrument No. 71/2019)**** replacing the existing factors "(b)" and "(p)" in clause 6 concerning 'being in an atmosphere with a visible tobacco smoke haze' with factors for 'being exposed to second-hand smoke' numbered "(b)", "(ba)", "(p)" and "(pa)"; and
* inserting a definition of 'being exposed to second-hand smoke' in clause 9 in alphabetical order.

***For BoP SoP*** ***(Instrument No. 72/2019)**** inserting new factors "(ab)", "(ac)", "(na)" and "(nb)" in clause 6 concerning 'being exposed to second-hand smoke'; and
* inserting a definition of 'being exposed to second-hand smoke' in clause 9 in alphabetical order.

**The determining of these Instruments finalises the investigation in relation to *aortic aneurysm* as advertised in the Government Notices Gazette of 8 January 2019.** |
| 73 & 74/2019 |  | **Amendment**These instruments amend Statements of Principles Nos. 61 & 62 of 2017 concerning ***osteoarthitis*** by:***For RH & BoP SoPs*** ***(Instrument Nos. 73 & 74/2019)**** replacing the definition of 'osteoarthritis' in subsection 7(2).

**The determining of these Instruments finalises the investigation in relation to *osteoarthritis* as advertised in the Government Notices Gazette of 7 May 2019.** |
| 75 & 76/2019 |  | **Amendment**These instruments amend Statements of Principles Nos. 5 & 6 of 2014 concerning ***morbid obesity*** by:***For RH & BoP SoPs*** ***(Instrument Nos. 75 & 76/2019)**** replacing the definition of 'morbid obesity' in clause 3(b); and
* revising the existing definition of 'BMI' in clause 9.

**The determining of these Instruments finalises the investigation in relation to *morbid obesity* as advertised in the Government Notices Gazette of 12 March 2019.** |